Table 2 Changes in liver fibrosis markers after DAA treatment.

From: Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents

 

Baseline

48 W

96 W

144 W

p-value†

Liver stiffness, kPa

19.37 ± 12.86

13.88 ± 9.13

11.70 ± 8.23

10.09 ± 6.23

 < 0.001

FIB-4

6.29 ± 4.67

3.25 ± 2.14

2.87 ± 1.59

2.89 ± 1.70

 < 0.001

APRI

1.36 ± 0.86

0.66 ± 0.62

0.50 ± 0.29

0.43 ± 0.21

 < 0.001

  1. †K-paired sample Friedman tests were used as normality tests were not satisfied.
  2. DAA, direct antiviral agent; FIB-4, fibrosis-4; APRI, Aspartate transaminase to platelet ratio index; W, week.
Back to article page